Inspira Technologies Oxy Bhn Ltd Stock Price, News & Analysis

Inspira Technologies (Nasdaq: IINN) reported its Q1 2022 financial results, announcing a net loss of $1.3 million, significantly down from $7.2 million in Q1 2021. The company had $21.7 million in cash as of March 31, 2022. R&D expenses rose to $1.5 million, driven by hiring specialized staff. Marketing and general administrative expenses also increased to $472,000 and $1.5 million, respectively. Inspira is focused on FDA submissions for its ART system and has secured strategic agreements potentially worth $212 million over seven years.

Inspira Technologies OXY B.H.N. Ltd. (Nasdaq: IINN) has announced its participation in several key events in May 2022, showcasing its innovative respiratory support technology. Highlights include the Medtech Forum in Barcelona from May 3-5, featuring VP Adi Rizansky Nir, and the EuroELSO Congress in London from May 4-6, with CTO Daniella Yeheskely-Hayon. The company will also present at the Sidoti Virtual Microcap Conference on May 11 and engage in a Fireside Chat at the Benzinga Virtual All Access Show on May 20, led by CFO Joe Hayon.

The company’s ART device aims to support respiratory patients efficiently.

Inspira Technologies announced a summary distribution agreement with Bepex Ltd. aimed at deploying its Augmented Respiration Technology (ART) systems in Israel's medical centers. This partnership follows three prior agreements collectively targeting approximately $386M in the U.S. and European markets, pending regulatory approvals. The initial term of the agreement is set for seven years. The ART system is projected to provide innovative care for acute respiratory failure, potentially reducing reliance on invasive mechanical ventilation.

Inspira Technologies OXY B.H.N. Ltd. (Nasdaq: IINN) has published its financial results for 2021, available on its Investor Relations website. The report outlines key metrics and insights from the company's operations over the past year. For a detailed overview, stakeholders are encouraged to view the CEO update linked in the announcement.

Inspira Technologies has been awarded the 2021 Europe Technology Innovation Leadership Award by Frost & Sullivan for its ART system, a novel respiratory support technology. Designed to be a second-line treatment, the ART minimizes the need for invasive mechanical ventilation (MV) by optimizing oxygen saturation while patients are awake. The ART system uses a low-flow approach, reducing health risks associated with traditional methods like ECMO. The company plans to submit a FDA filing for the ART system in H2-2023, marking significant strides in the respiratory care market.

Inspira Technologies OXY B.H.N. Ltd. (Nasdaq: IINN) has received the 2021 Europe Technology Innovation Leadership Award in the artificial respiratory market from Frost & Sullivan. This recognition highlights the innovative ART™ system, which aims to reduce the reliance on invasive mechanical ventilation. Frost & Sullivan praised ART for its plug-and-play simplicity and its potential to improve patient care by minimizing lung damage. Despite this progress, the ART system has not yet been approved by the FDA or other regulatory bodies, leaving its market viability uncertain.

Inspira Technologies (Nasdaq: IINN) announced that President & CFO Joe Hayon will present at the Aegis Virtual Event on February 23, 2022, at 8:30am EST. The presentation can be accessed here. Inspira focuses on innovative respiratory technology, developing the ART system to serve as an early extracorporeal support solution, potentially reducing the need for invasive ventilation. The product is still under development and has not received regulatory approval.

Inspira Technologies OXY B.H.N. Ltd. (Nasdaq: IINN, IINNW) announced the appointment of Daniella Yeheskely-Hayon, PhD, as Chief Technology Officer. She brings extensive experience in biomedical engineering, particularly in blood oxygenation and ECMO devices. Yeheskely-Hayon will lead the research and development of the company’s oxygenators and sensors. Inspira Technologies aims to establish its ART system as a new care standard for acute respiratory patients, although the product has not yet undergone human testing or received regulatory approval.

Inspira Technologies (Nasdaq: IINN) announced an exclusive distribution agreement with Glo-Med Networks for their respiratory support system across six U.S. states, including Texas and Florida. This agreement, with an initial term of seven years, aims to deploy a minimum of 2,121 ART systems and 131,413 disposable units, subject to regulatory approvals. The company projects a potential $174 million market opportunity in Europe, building on previous agreements. Inspira aims to enhance its U.S. market presence and improve respiratory treatment for patients in need.